The primary objectives are to determine the progression-free survival (PFS) and to evaluate safety of the trastuzumab, bevacizumab and docetaxel regimen. up to 12 months [clinicaltrials_resource:1c720284bdd5d495a451e81ac9e205d0]
Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
The primary objectives are to determine the progression-free survival (PFS) and to evaluate safety of the trastuzumab, bevacizumab and docetaxel regimen. up to 12 months [clinicaltrials_resource:1c720284bdd5d495a451e81ac9e205d0]
Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
Bio2RDF identifier
1c720284bdd5d495a451e81ac9e205d0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1c720284bdd5d495a451e81ac9e205d0
measure [clinicaltrials_vocabulary:measure]
The primary objectives are to ...... cizumab and docetaxel regimen.
time frame [clinicaltrials_vocabulary:time-frame]
up to 12 months
description
Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
identifier
clinicaltrials_resource:1c720284bdd5d495a451e81ac9e205d0
title
The primary objectives are to ...... taxel regimen. up to 12 months
@en
type
label
The primary objectives are to ...... 20284bdd5d495a451e81ac9e205d0]
@en